Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06610344 · ClinicalTrials.gov registry record · NA
BHB & CAR-T for Lymphomas
A NA study of Large B-cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06610344: Recruiting NA study of Large B-cell Lymphoma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06610344 is a NA study of Large B-cell Lymphoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 5 participants, below the 159-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06610344, a NA study of Large B-cell Lymphoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) to determine whether BHB supplementation is safe and tolerable in this patient population. Additionally, this study will determine whether BHB supplementation leads to changes the gut microbiome and peripheral blood mononuclear cells (PBMCs). BHB supplementation will be performed through oral administration of HVMN Ketone-IQ, a commercially available BHB supplement, with an active ingredient of R- 1,3-Butanediol, which is converted to BHB.
Primary Outcome
Assess number and severity of adverse events as well as number of patients who complete treatment
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT R-1,3-Butanediol
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2027-09-15 |
| Phase | NA |
What NCT06610344 shows while recruiting
NCT06610344 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 159-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which R-1,3-Butanediol is the first listed.
NCT06610344 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06610344 about?
NCT06610344 is a clinical study titled "BHB & CAR-T for Lymphomas". The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) to determine whether BHB supplementation is safe and tolerable in this patient population. Additiona...
What is the current status of trial NCT06610344?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2025-01-07. Estimated completion is 2027-09-15.
What conditions does trial NCT06610344 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06610344?
The interventions under investigation include: R-1,3-Butanediol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06610344?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06610344 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06610344's enrollment target sits among peer trials
5 29th of 28 the lowest of 28 other Large B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Large B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
CAR-T Followed by Bispecific Antibodies
RECRUITING · Phase 2
-
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI